Biomarkers of axonal damage to favor early diagnosis in variant transthyretin amyloidosis (A-ATTRv)
Scientific Reports – Biomarkers of axonal damage to favor early diagnosis in variant transthyretin amyloidosis (A-ATTRv)
Scientific Reports – Biomarkers of axonal damage to favor early diagnosis in variant transthyretin amyloidosis (A-ATTRv)
Frontline amivantamab with chemotherapy has been recommended for approval by the CHMP in EGFR exon 20 insertion+ non–small cell lung cancer.
CHMP has voiced its support for the approval of fruquintinib in previously treated metastatic colorectal cancer.
Gerard Walls, MB MRCP MSc FRCR, Queens University in Belfast, UK, discusses the NI-HEART analysis aimed at addressing the challenges of collecting cardiac toxicity events…
Ernst Holler, MD, University Hospital Regensburg, Regensburg, Germany, gives an overview of the relationship between the gut microbiome and graft-versus-host disease (GvHD). A loss of…
October, 2024, will see the 10-year anniversary of The Lancet Haematology, which was first published in 2014. To mark this occasion, we are publishing a…
Frontline nivolumab plus chemotherapy has been recommended for approval in unresectable or metastatic urothelial carcinoma.
Robert W. Mutter, MD, discusses personalized treatment approaches with radiation and endocrine therapy with
The phase 2 DENALI trial is investigating azenosertib in patients with high-grade serous ovarian cancer.
Kian-Huat Lim, MD, PhD, discusses the current treatment landscape for metastatic pancreatic cancer.
Glecirasib elicited responses and demonstrated a manageable safety profile in patients with pretreated advanced NSCLC harboring KRAS G12C mutations.